Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: the Korean Society of Pediatric Hematology-Oncology experience over 6 years (2000-2005)

• Published in: Journal of Korean medical science Vol. 25; no. 5; pp. 691 - 697
• Main Authors: Sung, Ki Woong, Ahn, Hyo Seop, Cho, Bin, Choi, Yong-Mook, Chung, Nack Gyun, Hwang, Tai Ju, Im, Ho Joon, Jeong, Dae Chul, Kang, Hyoung Jin, Koo, Hong Hoe, Kook, Hoon, Kim, Hack Ki, Lyu, Chuhl Joo, Seo, Jong Jin, Shin, Hee Young, Yoo, Keon Hee, Won, Sung Chul, Lee, Kun Soo
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Academy of Medical Sciences 01.05.2010; 대한의학회
• Subjects: Adolescent; Child; Child, Preschool; Combined Modality Therapy - mortality; Drug Therapy - mortality; Female; Humans; Infant; Korea - epidemiology; Longitudinal Studies; Male; Neuroblastoma - mortality; Neuroblastoma - therapy; Original; Prevalence; Risk Assessment - methods; Risk Factors; Stem Cell Transplantation - mortality; Survival Analysis; Survival Rate; Treatment Outcome; 의학일반; Korea; Transplantation, Autologous; High-dose Chemotherapy; Neuroblastoma
• ISSN: 1011-8934; 1598-6357
• DOI: 10.3346/jkms.2010.25.5.691

The efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was investigated in patients with high-risk neuroblastoma. Patients over 1 yr of age who were newly diagnosed with stage 4 neuroblastoma from January 2000 to December 2005 were enrolled in The Korean Society of Pediatric Hematology-Oncology registry. All patients who were assigned to receive HDCT/ASCR at diagnosis were retrospectively analyzed to investigate the efficacy of single or tandem HDCT/ASCR. Seventy and 71 patients were assigned to receive single or tandem HDCT/ASCR at diagnosis. Fifty-seven and 59 patients in the single or tandem HDCT group underwent single or tandem HDCT/ASCR as scheduled. Twenty-four and 38 patients in the single or tandem HDCT group remained event free with a median follow-up of 56 (24-88) months. When the survival rate was analyzed according to intent-to-treat at diagnosis, the probability of the 5-yr event-free survival+/-95% confidence intervals was higher in the tandem HDCT group than in the single HDCT group (51.2+/-12.4% vs. 31.3+/-11.5%, P=0.030). The results of the present study demonstrate that the tandem HDCT/ASCR strategy is significantly better than the single HDCT/ASCR strategy for improved survival in the treatment of high-risk neuroblastoma patients.